期刊文献+

中国健康志愿者单次静滴甲磺酸加替沙星氯化钠注射液耐受性研究

The Tolerance of Gatifloxacin Mehanesulfanae after Single- Does Intravenous Infusion in Chinses Health Volunteers
下载PDF
导出
摘要 目的:在中国健康成年志愿者中评价单次静滴甲磺酸加替沙星氯化钠注射液的安全性、耐受性.方法:根据新药临床试验指导原则设计试验方案,并获得伦理委员会批准.受试者须自愿签署知情同意书.选择48名18~50岁健康成人,经体检及实验室检查均在正常范围内.用区组随机化设计方法,将受试者随机分配至100mg、200mg、300mg、400mg、500mg、600mg、700mg、800mg剂量组中,每组6名,男女各半.观察指标为临床症状体征,实验室指标包括心电图、脑电图、血常规、凝血功能、尿常规、肝功能、肾功能、电解质等.严密观察记录试验期间发生的不良事件.结果:各组入选受试者体检及实验室检查各项指标测定值均在正常范围,条件均衡,具较好可比性.给药后体温、呼吸频率、脉搏、血压、血常规、尿常规、肾功能、电解质、心电图、脑电图等未见有临床意义的改变.试验中未见严重的临床不良反应,只发现3例次可能与药物有关的轻度-过性不良反应,分别表现为面部瘙痒、皮疹、GOT或GPT升高.结论:健康受试者单次静滴甲磺酸加替沙星氯化钠注射液,最大剂量至800mg,比较安全、耐受性较好.推荐临床使用剂量为400mg/次/日.
出处 《中国药物应用与监测》 CAS 2003年第1期46-50,共5页 Chinese Journal of Drug Application and Monitoring
  • 相关文献

参考文献12

  • 1[1]Hosaka M, Kinoshita S, Toyama A, et al. Antibacterial properties of AM- 1155, a new 8- methoxy quinolone. J Antimicrob Chemther, 1995,36: 293.
  • 2[2]Tomioka H,Saito H,Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM 1155, sparfloxacin and ofloxacin. Antimicrob Agents Chemother, 1993,37(6): 1259.
  • 3[3]Wakabayshi E, Mitsuhashi S. In vitro antibacterial activitiy of AM - 1155 a, novel 6 - fluoro- 8 - nethoxy quinolone. Antimicrob Agents Chemother, 1994,38 (3):594.
  • 4[4]Appelbaum PC. Quinolone activity against anaerobes. Drugs, 1999,58 Suppl 2:60.
  • 5[5]Miyashita N,Niki Y,Kishimono T,et al. In vitro and in vivo activities of AM- 1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob Agents Chemother, 1997,41(6):1331.
  • 6[8]JLM. Oral and i.v. formulations of gatifoxacin cleared for U. S market. Am J Health - Syst Pharm,2000,57:204.
  • 7[9]Hosaka M,Yasue T,Fukuda H,et al. In vitro and in vivo antibacterial activities of AM - 1155, a new 6 - fluoro- 8 - methoxy quinolone. Antimicrob Agents Chemother, 1992,36(10) :2108.
  • 8[10]Takei M, Fukuda H, Yasue T, et al. Inhibitory activities of gatifloxacin(AM- 1155), a newly developed fluoro quinolone, against bacterial and mammalian type Ⅱ topoisomerase. Antimicro Agents Chemother, 1998,42 ( 20 ): 2678.
  • 9[11]Lober S, Ziege S, Rau M, et al. Pharmcokinetics of gatifoxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother,1999,43(5) :1067.
  • 10[12]Stahlberg HJ, Gohler K, Guillane M, et al. Effects of gati floxacin(GTX)on the pharmacokinetics of theophyline in heathly young volunteers [ abstract ]. J Antimicrob Chemther. 1999,44 suppl. A: 136.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部